DAY 5:
Comparing the molnupiravir group to the placebo group, a significant reduction in viral RNA load was seen from baseline. (WMD: -0.46; 95% CI; [-0.77,-0.15] p=0.004; I²=0%) (Fig 4B)
Overall: The pooled analysis of molnupiravir 400mg shows significant outcome for the result (WMD: -0.28; 95% CI; [-0.49,-0.07] p=0.009; I²=0%) (Fig 4C)